FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2044293078> ?p ?o ?g. }

• W2044293078 endingPage "6161" @default.
• W2044293078 startingPage "6155" @default.
• W2044293078 abstract "Abstract To determine whether in vivo T-cell depletion, which lowers GVHD, abrogates the antileukemic benefits of myeloablative total body irradiation–based conditioning and unrelated donor transplantation, in the present study, we analyzed 715 children with acute lymphoblastic leukemia. Patients were grouped for analysis according to whether conditioning included antithymocyte globulin (ATG; n = 191) or alemtuzumab (n = 132) and no in vivo T-cell depletion (n = 392). The median follow-up time was 3.5 years for the ATG group and 5 years for the alemtuzumab and T cell–replete groups. Using Cox regression analysis, we compared transplantation outcomes between groups. Compared with no T-cell depletion, grade 2-4 acute and chronic GVHD rates were significantly lower after in vivo T-cell depletion with ATG (relative risk [RR] = 0.66; P = .005 and RR = 0.55; P < .0001, respectively) or alemtuzumab (RR = 0.09; P < .003 and RR = 0.21; P < .0001, respectively). Despite lower GVHD rates after in vivo T-cell depletion, nonrelapse mortality, relapse, overall survival, and leukemia-free survival (LFS) did not differ significantly among the treatment groups. The 3-year probabilities of LFS after ATG-containing, alemtuzumab-containing, and T cell–replete transplantations were 43%, 49%, and 46%, respectively. These data suggest that in vivo T-cell depletion lowers GVHD without compromising LFS among children with acute lymphoblastic leukemia who are undergoing unrelated donor transplantation with myeloablative total body irradiation–based regimens." @default.
• W2044293078 created "2016-06-24" @default.
• W2044293078 creator A5000705580 @default.
• W2044293078 creator A5008963719 @default.
• W2044293078 creator A5009145909 @default.
• W2044293078 creator A5017952176 @default.
• W2044293078 creator A5028145044 @default.
• W2044293078 creator A5030646889 @default.
• W2044293078 creator A5041346359 @default.
• W2044293078 creator A5047178145 @default.
• W2044293078 creator A5050460822 @default.
• W2044293078 creator A5053215443 @default.
• W2044293078 creator A5058210945 @default.
• W2044293078 creator A5061463272 @default.
• W2044293078 creator A5062964407 @default.
• W2044293078 creator A5069466344 @default.
• W2044293078 creator A5072495344 @default.
• W2044293078 creator A5073848195 @default.
• W2044293078 creator A5074795107 @default.
• W2044293078 creator A5075419577 @default.
• W2044293078 creator A5076234152 @default.
• W2044293078 creator A5078622686 @default.
• W2044293078 creator A5087156523 @default.
• W2044293078 date "2012-06-21" @default.
• W2044293078 modified "2023-10-13" @default.
• W2044293078 title "Impact of immune modulation with in vivo T-cell depletion and myleoablative total body irradiation conditioning on outcomes after unrelated donor transplantation for childhood acute lymphoblastic leukemia" @default.
• W2044293078 cites W1559103536 @default.
• W2044293078 cites W1979593849 @default.
• W2044293078 cites W1980914191 @default.
• W2044293078 cites W1997989186 @default.
• W2044293078 cites W1998210957 @default.
• W2044293078 cites W2003243407 @default.
• W2044293078 cites W2005604237 @default.
• W2044293078 cites W2008928916 @default.
• W2044293078 cites W2033153380 @default.
• W2044293078 cites W2045466423 @default.
• W2044293078 cites W2057144497 @default.
• W2044293078 cites W2065438642 @default.
• W2044293078 cites W2065984640 @default.
• W2044293078 cites W2069377065 @default.
• W2044293078 cites W2133104010 @default.
• W2044293078 cites W2159356276 @default.
• W2044293078 cites W2164885965 @default.
• W2044293078 cites W2166251447 @default.
• W2044293078 cites W4214512856 @default.
• W2044293078 cites W4247507468 @default.
• W2044293078 doi "https://doi.org/10.1182/blood-2012-01-405795" @default.
• W2044293078 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3383023" @default.
• W2044293078 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22573402" @default.
• W2044293078 hasPublicationYear "2012" @default.
• W2044293078 type Work @default.
• W2044293078 sameAs 2044293078 @default.
• W2044293078 citedByCount "36" @default.
• W2044293078 countsByYear W20442930782012 @default.
• W2044293078 countsByYear W20442930782013 @default.
• W2044293078 countsByYear W20442930782014 @default.
• W2044293078 countsByYear W20442930782015 @default.
• W2044293078 countsByYear W20442930782016 @default.
• W2044293078 countsByYear W20442930782017 @default.
• W2044293078 countsByYear W20442930782018 @default.
• W2044293078 countsByYear W20442930782019 @default.
• W2044293078 countsByYear W20442930782020 @default.
• W2044293078 countsByYear W20442930782021 @default.
• W2044293078 countsByYear W20442930782022 @default.
• W2044293078 countsByYear W20442930782023 @default.
• W2044293078 crossrefType "journal-article" @default.
• W2044293078 hasAuthorship W2044293078A5000705580 @default.
• W2044293078 hasAuthorship W2044293078A5008963719 @default.
• W2044293078 hasAuthorship W2044293078A5009145909 @default.
• W2044293078 hasAuthorship W2044293078A5017952176 @default.
• W2044293078 hasAuthorship W2044293078A5028145044 @default.
• W2044293078 hasAuthorship W2044293078A5030646889 @default.
• W2044293078 hasAuthorship W2044293078A5041346359 @default.
• W2044293078 hasAuthorship W2044293078A5047178145 @default.
• W2044293078 hasAuthorship W2044293078A5050460822 @default.
• W2044293078 hasAuthorship W2044293078A5053215443 @default.
• W2044293078 hasAuthorship W2044293078A5058210945 @default.
• W2044293078 hasAuthorship W2044293078A5061463272 @default.
• W2044293078 hasAuthorship W2044293078A5062964407 @default.
• W2044293078 hasAuthorship W2044293078A5069466344 @default.
• W2044293078 hasAuthorship W2044293078A5072495344 @default.
• W2044293078 hasAuthorship W2044293078A5073848195 @default.
• W2044293078 hasAuthorship W2044293078A5074795107 @default.
• W2044293078 hasAuthorship W2044293078A5075419577 @default.
• W2044293078 hasAuthorship W2044293078A5076234152 @default.
• W2044293078 hasAuthorship W2044293078A5078622686 @default.
• W2044293078 hasAuthorship W2044293078A5087156523 @default.
• W2044293078 hasBestOaLocation W20442930781 @default.
• W2044293078 hasConcept C126322002 @default.
• W2044293078 hasConcept C150903083 @default.
• W2044293078 hasConcept C203014093 @default.
• W2044293078 hasConcept C207001950 @default.
• W2044293078 hasConcept C2776694085 @default.
• W2044293078 hasConcept C2776755627 @default.
• W2044293078 hasConcept C2778461978 @default.
• W2044293078 hasConcept C2778880498 @default.
• W2044293078 hasConcept C2779015954 @default.
• W2044293078 hasConcept C2781107101 @default.

• next